Based on the results of PROGRESS and the previous RELIEF-DPN-1 study, the 10 mg dose of pilavapadin was selected to move forward in clinical development for diabetic peripheral neuropathic pain.:
Source: Neurology Read More
Pilavapadin Heads for Phase 3 Trial Following Positive PROGRESS Study of Neuropathic Pain
Related Posts
<![CDATA[Once-Daily Alixorexton Improves Cognition,
Fatigue, and Disease Severity in Phase 2 Narcolepsy Type 1
Study]]>
<![CDATA[Once-Daily Alixorexton Improves Cognition, Fatigue, and Disease Severity in Phase 2 Narcolepsy Type 1 Study]]>
